Pharmaceutical

ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia

Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.

Jun 3, 2025 - 06:00
ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia
Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.
Read the original article

Tags:

Previous Article

Regeneron to acquire rights for Hansoh’s HS-20094 therapy

Next Article

BMS outlays $11bn to join BioNTech’s development of bispecific cancer drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

An uncommon thyroid diagnosis led to an unexpected, all-too-visible side effect

An uncommon thyroid diagnosis led to an unexpected, all...

Sep 8, 2023

Having celiac disease and a thyroid condition sent her on a quest to become an empathetic doctor

Having celiac disease and a thyroid condition sent her ...

Aug 19, 2023

Dexmedetomidine by Teikoku Pharma USA for Post-Operativ...

Jul 7, 2023